Sam Blackman, Founder and Head of Research and Development of Day One Biopharmaceuticals, is a physician-scientist trained in pediatric hematology/oncology and pediatric neuro-oncology. He has led the early clinical development of more than 10 novel cancer therapeutics. Prior to founding Day One, Dr. Blackman held roles of increasing responsibility at Silverback Therapeutics, Juno Therapeutics, Seattle Genetics, Merck, and GlaxoSmithKline. Dr. Blackman was responsible for the pediatric development of dabrafenib, resulting in the first industry-sponsored pediatric oncology “basket trial”. Through roles at CureSearch for Children’s Cancer, and ACCELERATE, Dr. Blackman has been an active leader in the pediatric oncology drug development community. He is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his MD and PhD from the University of Illinois at Chicago, and his undergraduate degree in Philosophy from the University of Chicago.